These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 20084020

  • 1. Expression of PROX1 Is a common feature of high-grade malignant astrocytic gliomas.
    Elsir T, Eriksson A, Orrego A, Lindström MS, Nistér M.
    J Neuropathol Exp Neurol; 2010 Feb; 69(2):129-38. PubMed ID: 20084020
    [Abstract] [Full Text] [Related]

  • 2. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR, Elsir T, Edqvist PD, Hägerstrand D, Carlson J, Lysiak M, Henriksson R, Pontén F, Rosell J, Söderkvist P, Stupp R, Tchougounova E, Nistér M, Malmström A, Smits A.
    Oncotarget; 2016 Nov 08; 7(45):72431-72442. PubMed ID: 27626492
    [Abstract] [Full Text] [Related]

  • 3. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.
    Erdamar S, Bagci P, Oz B, Dirican A.
    J BUON; 2006 Nov 08; 11(2):213-6. PubMed ID: 17318973
    [Abstract] [Full Text] [Related]

  • 4. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.
    Geiger KD, Stoldt P, Schlote W, Derouiche A.
    Am J Pathol; 2000 Dec 08; 157(6):1785-93. PubMed ID: 11106550
    [Abstract] [Full Text] [Related]

  • 5. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
    Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S.
    Cancer; 2003 Dec 01; 98(11):2430-9. PubMed ID: 14635078
    [Abstract] [Full Text] [Related]

  • 6. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
    Capper D, Mittelbronn M, Meyermann R, Schittenhelm J.
    Acta Neuropathol; 2008 Feb 01; 115(2):249-59. PubMed ID: 17965865
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
    Bodey B, Bodey B, Siegel SE, Kaiser HE.
    In Vivo; 1999 Feb 01; 13(4):357-73. PubMed ID: 10586378
    [Abstract] [Full Text] [Related]

  • 9. Expression and release of CD14 in astrocytic brain tumors.
    Deininger MH, Meyermann R, Schluesener HJ.
    Acta Neuropathol; 2003 Sep 01; 106(3):271-7. PubMed ID: 12835948
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumors.
    Blümcke I, Müller S, Buslei R, Riederer BM, Wiestler OD.
    Acta Neuropathol; 2004 Aug 01; 108(2):89-96. PubMed ID: 15146346
    [Abstract] [Full Text] [Related]

  • 12. Vascular endothelial growth factor (VEGF) receptor neuropilin-1's distribution in astrocytic tumors.
    Broholm H, Laursen H.
    APMIS; 2004 Aug 01; 112(4-5):257-63. PubMed ID: 15233640
    [Abstract] [Full Text] [Related]

  • 13. Coexpression of epidermal growth factor receptor protein and c-erbB-2 oncoprotein in human astrocytic tumors. An immunohistochemical study.
    Dietzmann K, von Bossanyi P.
    Zentralbl Pathol; 1994 Nov 01; 140(4-5):335-41. PubMed ID: 7826981
    [Abstract] [Full Text] [Related]

  • 14. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.
    Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K.
    Cancer; 2003 Feb 15; 97(4):1077-83. PubMed ID: 12569609
    [Abstract] [Full Text] [Related]

  • 15. Microvessel density in brain tumors.
    Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Papadakis N, Varakis I.
    Anticancer Res; 1997 Feb 15; 17(6D):4747-53. PubMed ID: 9494601
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characteristics of tumour vessels in cytological squash smears of astrocytic tumours.
    Sato S, Sato Y, Marutsuka K, Takeshima H, Asada Y.
    Cytopathology; 2011 Oct 15; 22(5):313-7. PubMed ID: 21039979
    [Abstract] [Full Text] [Related]

  • 18. Geminin: a good prognostic factor in high-grade astrocytic brain tumors.
    Shrestha P, Saito T, Hama S, Arifin MT, Kajiwara Y, Yamasaki F, Hidaka T, Sugiyama K, Kurisu K.
    Cancer; 2007 Mar 01; 109(5):949-56. PubMed ID: 17262828
    [Abstract] [Full Text] [Related]

  • 19. Tenascin expression in astrocytomas correlates with angiogenesis.
    Zagzag D, Friedlander DR, Miller DC, Dosik J, Cangiarella J, Kostianovsky M, Cohen H, Grumet M, Greco MA.
    Cancer Res; 1995 Feb 15; 55(4):907-14. PubMed ID: 7531617
    [Abstract] [Full Text] [Related]

  • 20. Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression.
    Benzil DL, Finkelstein SD, Epstein MH, Finch PW.
    Cancer Res; 1992 May 15; 52(10):2951-6. PubMed ID: 1316231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.